MedTrace Logo

Tolerability and Toxicity of Topically Applied Nepafenac 0.3% vs Ketorolac 0.5%

NCT02752646 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2017-03-07

No results posted yet for this study

Summary

This study will examine the tolerability and toxicity of topically applied Nepafenac 0.3% vs ketorolac 0.5% among patients undergoing cataract surgery.

Conditions

  • Cataract

Interventions

DRUG

nepafenac 0.3%

Patients in this group will receive nepafenac 0.3% eye drops once daily after cataract surgery.

DRUG

ketorolac

Patients in this group will receive ketorolac 0.5% eye drops four times daily after cataract surgery.

Sponsors & Collaborators

  • Alcon Research

    collaborator INDUSTRY

  • MDbackline, LLC

    lead OTHER

Principal Investigators

  • John A Hovanesian, MD · UCLA Jules Stein Eye Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2017-03-01
Completion
2017-03-01

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02752646 on ClinicalTrials.gov